Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review

“`html

Improved Diagnosis and Treatment for Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations

Study Overview

• Reviewed 395 MDS patients at our center from 2018 to 2023
• Identified 39 patients with lower-risk MDS and SF3B1 mutations
• Supports the revised 2022 definitions of the World Health Organization (WHO) and International Consensus Classification (ICC)

Key Findings

• Lower-risk MDS-RS patients had reduced transfusion dependency with luspatercept treatment
• A quarter of patients would be missed using only the morphologic criterion of RS greater than 15%
• Supports the shift toward molecularly defined subtypes of MDS and appropriate testing

Source: Curr Oncol. 2024 Mar 29;31(4):1762-1773

“`

Full research Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review: https://pubmed.ncbi.nlm.nih.gov/38668037/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1B1L42DK3a-JWCV4P_PtHHBmWjwBLFNcDXsYJkbqjQD0Ca7UQh&fc=None&ff=20240426163055&v=2.18.0.post9+e462414